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We present the case of a 72-year-old female with a major depressive episode who developed hyponatremia associated with
bupropion. In reviewing the literature, there are only a few case reports which pertain to this topic. The clinical symptoms
of hyponatremia can be misinterpreted as a worsening of the primary psychiatric illness and can lead to potentially serious
consequences if not fully evaluated. We recommend that clinicians should be well aware of this side effect and that sodium levels
should be checked within the first 2 weeks after initiating treatment in patients, especially those with additional risk factors for
hyponatremia, such as older age, female sex, diuretic use, low BMI, and unexplained mental status changes at any time during
treatment with antidepressants. The risk for hyponatremia associated with mirtazapine appears to be low and its use can be helpful
in patients who have developed hyponatremia induced by other antidepressants and who experienced symptoms of weight loss and
insomnia.
1. Introduction
Bupropion is an antidepressant which acts by inhibiting
the reuptake of dopamine and noradrenaline. Although
hyponatremia has been reported to be associated with use
of various antidepressants, especially selective serotonin
reuptake inhibitors (SSRIs) and serotonin norepinephrine
reuptake inhibitors (SNRIs), it has rarely been reported
with bupropion. Some authors hypothesize that hypona-
tremia is due to an antidepressant’s potency to inhibit the
reuptake of serotonin, thought to be due to a serotonin-
induced increase in ADH, andmediated by the hypothalamic
serotonin receptors. Alternatively, the limited evidence of
bupropion as a causative agent of hyponatremia suggests
that the mechanisms by which antidepressants can provoke
hyponatremia may not only be related to their potential to
inhibit serotonergic reuptake.
2. History of Present Illness
Ms. A was a 72-year-old single female, referred by her
primary care provider (PCP) for evaluation of worsening
depression. The patient was diagnosed with depression in
her early twenties and was reportedly stable since, being
productive and working as a clerk for fifty years. She never
married and lived alone. She retired last year and quickly
began to get more depressed and socially withdrawn, not
eating with an unintentional weight loss of over 30 pounds
in the past few months and overall not caring for herself.
She reported anxiety related to her finances despite being
financially secure. She had passive suicidal ideation of putting
a cover over her head and “just going to sleep.” She admits
having feelings of hopelessness, poor sleep, poor appetite, and
despair related to not getting better. She now weighs about
80l bs, down from her baseline of 110 pounds. She denied any
history of substance use or any manic symptoms. In the past
four months, her PCP prescribed escitalopram which was
titrated from 10mg to 20mg daily and alprazolam 0.25mg
tid, resulting in minimal clinical response. Pt. was not on any
other medications at the time of admission.
3. Course of Hospitalization
Patient was started on bupropion 37.5mg PO BID with
clonazepam 0.25mg BID to target the symptoms of
depression and anxiety. Pt. was tolerating the medication
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Figure 1: Serum sodium levels through the hospital stay.
well and the dose was titrated up to 75mg BID in a few
days. Patient’s sodium level at admission was 132MEQ/L
(135–150). Also, her other basic laboratory tests were within
normal limits including TSH, T4, BUN, and creatinine. After
2 weeks, the patient started to develop acute mental status
changes, becoming more confused and lethargic and a repeat
sodium level was taken and was 125MEQ/L. A medicine
consult was called and assessed the likely cause of the
hyponatremia as being due to medication since the patient
did not have any significant GI symptoms or polydipsia. A
provisional diagnosis of bupropion induced hyponatremia
was made and the medication was stopped. The patient was
subsequently started on mirtazapine 7.5mgQhs. Five days
after stopping the bupropion, the sodium level increased
to 130MEQ/L and then to baseline at 135MEQ/L in about
ten days after discontinuation of bupropion (Figure 1). The
patient responded well to mirtazapine with reduction in
depressive symptoms, increased appetite, and weight gain.
4. Discussion
Antidepressants, including the selective serotonin reup-
take inhibitor (SSRI), serotonin norepinephrine reuptake
inhibitor (SNRI), and tricyclic antidepressants (TCA), can
cause hyponatremia [1, 2]. It is hypothesized that serotonin
induces an increase in ADH which is mediated by the
hypothalamic serotonin receptors and that the greater the
potency of the drug to inhibit the reuptake of serotonin, the
greater the chance of hyponatremia [3].
A study found that the serotonergic antidepressants
(SSRIs, venlafaxine, and clomipramine combined) were at a
greater risk for causing hyponatremia when compared with
other antidepressants (OR 3.96 versus 1.78, resp.) [4].
Bupropion’s primary pharmacological action is to inhibit
norepinephrine-dopamine reuptake. Although bupropion
does not act on serotonergic receptors, there are only a few
case reports describing howbupropion can be associatedwith
hyponatremia [5–7]. Animal studies have shown that both
serotonin and noradrenaline can increase ADH secretion
by stimulating serotonergic and 𝛼-adrenergic receptors [8,
9]. Bupropion therefore may cause hyponatremia by the
noradrenergic stimulation of vasopressin release.
Estimates of hyponatremia associated with SSRI and
SNRI use vary from 0.5 to 32% [7]. Aging is one of the
most significant risk factors for SSRI induced hyponatremia
and the incidence rates range from 12% to 33% in the
elderly population [10–12]. The cause of this may be due to
altered renal function, increased ADH secretion, increased
sensitivity to ADH, presence of concomitant illnesses, and
other medications that contribute to hyponatremia [10].
Other risk factors include diuretic drug use [13], recent or
current pneumonia, lower base line serum sodium levels, and
lower body mass index [11].
The German drug-surveillance program in psychiatric
inpatients could not detect a single case of hyponatremia
due to mirtazapine alone [3]. Also, as per Jung et al., there
were no cases of hyponatremiawithmirtazapine as compared
with 8% on SSRIs and 4% on venlafaxine [14]. It has also
been described that mirtazapine has been successfully used
in treating patients in whom hyponatremia had developed
previously while on an SSRI [15, 16].
Clinicians should be aware of the higher risk and signs
of hyponatremia associated with certain antidepressants, as
clinical symptoms of hyponatremia can be misinterpreted as
a worsening of the primary psychiatric illness.
It is recommended that sodium levels should be checked
in all elderly patients exhibiting abrupt or unexplained
changes in mental status (e.g., lethargy or confusion) at
any time during treatment with an SSRI, SNRI, and NDRI
medication [12]. Some recommend a routine serum sodium
level at start of therapy and within the first 2 weeks after
initiating such treatment, especially if the patients are older,
are female on diuretics, have low BMI, and have a baseline
plasma sodium level lower than 138MEQ/L [3, 12, 17, 18].
In our patient, the hyponatremia resolved once the
bupropion was stopped and subsequently had a good clin-
ical response to mirtazapine with no further hyponatremia
throughout the course of the hospital.
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